welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

key information

study id #: NCT01187901

condition: Adenomatous Polyposis Coli

status: completed


The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP patients.

Drug: Erlotinib
Drug: Sulindac
Drug: Placebo A
Drug: Placebo B

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.